Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

6986 results

Sort By:

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Study ID: NCT06616155
Start Date: 2026-01-30
End Date: 2030-01-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

39

Intervention / Treatment

Biopsy

Biospecimen Collection

Bone Scan

Computed Tomography

Enzalutamide

Ruxolitinib

Sponsor

University of Michigan Rogel Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Study ID: NCT05800015
Start Date: 2023-08-08
End Date: 2031-12-23
Study Type

Interventional

Study Phase

Phase3

No. of Participants

950

Intervention / Treatment

fianlimab

cemiplimab

Pemetrexed

Paclitaxel

Carboplatin

Cisplatin

Placebo

Sponsor

Regeneron Pharmaceuticals

Source: clinicaltrials.gov

Share:
Add to list

Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU

Study ID: NCT06538376
Start Date: 2023-12-12
End Date: 2027-11
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

230

Intervention / Treatment

Portable Dynamic Digital Radiography (DDR)

Sponsor

Brigham and Women's Hospital

Source: clinicaltrials.gov

Share:
Add to list

Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer

Study ID: NCT06736717
Start Date: 2025-02
End Date: 2027-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

21

Intervention / Treatment

Onvansertib

NALIRIFOX

Sponsor

University of Kansas Medical Center

Source: clinicaltrials.gov

Share:
Add to list

A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

Study ID: NCT06075810
Start Date: 2023-11-09
End Date: 2025-10-31
Study Type

Interventional

Study Phase

Phase1

No. of Participants

48

Intervention / Treatment

MBQ-167

Sponsor

MBQ Pharma

Source: clinicaltrials.gov

Share:
Add to list

GYNecologic Cancer-Related COGnitive Impairment

Study ID: NCT06662435
Start Date: 2025-02-07
End Date: 2028-12
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

60

Intervention / Treatment

Cock

Sponsor

Northwestern University

Source: clinicaltrials.gov

Share:
Add to list

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Study ID: NCT05691478
Start Date: 2023-03-03
End Date: 2030-03-20
Study Type

Interventional

Study Phase

Phase3

No. of Participants

1122

Intervention / Treatment

Bone Scan

Cabozantinib S-malate

Cisplatin

Computed Tomography

Doxorubicin Hydrochloride

Magnetic Resonance Imaging

Methotrexate

Surgical Procedure

X-Ray Imaging

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions

Study ID: NCT07048535
Start Date: 2025-10-24
End Date: 2029-07
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

80

Intervention / Treatment
Sponsor

St. Jude Children's Research Hospital

Source: clinicaltrials.gov

Share:
Add to list

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

Study ID: NCT06350097
Start Date: 2024-04-29
End Date: 2032-05-25
Study Type

Interventional

Study Phase

Phase3

No. of Participants

582

Intervention / Treatment

Osimertinib

Datopotamab Deruxtecan

Sponsor

AstraZeneca

Source: clinicaltrials.gov

Share:
Add to list

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Study ID: NCT06876662
Start Date: 2025-05-20
End Date: 2032-12
Study Type

Interventional

Study Phase

Phase4

No. of Participants

279

Intervention / Treatment

Pirtobrutinib

Sponsor

Eli Lilly and Company

Source: clinicaltrials.gov

Share:
Add to list